Verrica targets COVE-3 initiation by mid-2026 as Q1 dispensed YCANTH units rise 12.1% sequentially (NASDAQ:VRCA)


Earnings Call Insights: Verrica Pharmaceuticals (VRCA) Q1 2026

Management View

  • “I am pleased to report that in the first quarter, we saw accelerating growth in market demand for YCANTH, setting new records for dispensed applicator units during the quarter and in the

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.



Source link

Aussies stunned by Woolworths’ multi-step hiring process for supermarket workers

Amazon MGM Studios Names Mandy Schaffer, Craig Muhlrad As Heads Of TV

Leave a Reply

Your email address will not be published. Required fields are marked *